Luminex technology for anti-HLA antibody screening : evaluation of performance and of impact on laboratory routine by M. Colombo et al.
Luminex Technology for Anti-HLA Antibody
Screening: Evaluation of Performance and
of Impact on Laboratory Routine
Maria Bernadette Colombo,1 Simone Elisabeth Haworth,1 Francesca Poli,1* Angela Nocco,1
Giuseppe Puglisi,1 Annalisa Innocente,1 Marta Seraﬁni,1 Piergiorgio Messa,2
and Mario Scalamogna1
1Dipartimento di Medicina Rigenerativa, Fondazione Ospedale Maggiore, Policlinico, Mangiagalli, Regina
Elena, IRCCS, 20122 Milan, Italy
2Dipartimento dell’Area della Medicina e Specialita` Mediche, Fondazione Ospedale Maggiore, Policlinico,
Mangiagalli, Regina Elena, IRCCS, 20122 Milan, Italy
The recent introduction of new technologies such as Luminex has provided alternative methods to the
Complement Dependent Cytotoxicity (CDC) test for HLA speciﬁc antibody detection. In this study we com-
pared the results obtained with CDC to those obtained using a Luminex method with the aim of evaluating
the impact of this new technology on antibody screening policies in our transplant setting.
A total of 1,421 sera, acquired from patients on the waiting list for a kidney transplant or following
transplantation, were tested by both methodologies. CDC was performed using a whole lymphocyte popu-
lation comprising a panel of 52 cells. The percentage panel reactive antibodies (PRA) and antibody
speciﬁcity were evaluated using Lambda Scan Analysis software. For the Luminex method sera screening
and identiﬁcation of antibody speciﬁcity were carried out using the LABScreen Mixed and LABScreen
PRA respectively.
The overall concordance between the results obtained using the CDC and the Luminex methods was
85%. HLA antibody speciﬁcity was conﬁrmed in 96% of the sera which tested positive using the Luminex
system and serum positivity corresponded with a previous sensitisation event in these individuals. Using
the Luminex method 18% of patients on the waiting list were considered and managed as sensitised as
compared to 7% when testing with CDC alone. The Luminex method was able to detect a number of anti-
body speciﬁcities signiﬁcantly more frequently than the CDC method and in addition the CDC method
failed to detect some of the antibody speciﬁcities detected by the Luminex system.
Based on this comparison study we have incorporated the Luminex methodology into our screening
strategy. q 2007 Clinical Cytometry Society
Key terms: complement dependent cytotoxicity (CDC) test; HLA speciﬁc antibody detection; Luminex
technology
Since the ﬁrst evidence in 1969 that a positive cross-
match in kidney transplantation is associated with hyper
acute rejection of the transplanted organ (1), numerous
studies demonstrating the clinical relevance of anti-HLA
antibodies have been published (2–4). Because of the
implementation of Complement Dependent Cytotoxicity
test (CDC) cross-match testing in histocompatibility labo-
ratories, hyper acute rejection has become a rare event.
For more than 40 years the CDC test was the only
technique for detecting anti-HLA antibodies and it is still
the most frequently used method for pre-transplant
cross-match tests.
The introduction of less labor intensive techniques
such as ELISA and Flow Cytometry prompted many
laboratories to examine the new methodologies in com-
parison with CDC (5,6). One of the most consistent
observations is that Flow Cytometry and ELISA are more
sensitive with respect to standard serology, the former
being able to detect complement ﬁxing and complement
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nonﬁxing antibodies. The clinical signiﬁcance of non-
complement ﬁxing antibodies however is a subject of
debate (7–11). Furthermore, the increased sensitivity of
solid phase techniques has in turn increased the number
of patients with a detectable sensitization previously
considered as nonsensitized, which has resulted in reper-
cussions in the management of waiting lists.
More recently a new methodology has become avail-
able in histocompatibility laboratories. This system uses
micro beads coated with Class I or Class II HLA antigens
and a ﬂow analyzer. When appropriate a single antigen
assay allows conﬁrmation of antibody speciﬁcity.
We have introduced this technology, commonly
known as Luminex, into our laboratory, and used it in
parallel with the CDC test, for anti-HLA antibodies
screening for patients awaiting kidney transplantation
and kidney transplant recipients.
In this analysis we compared the results obtained with
CDC to those obtained using Luminex with the ultimate
aim of evaluating the impact of this new technology on
antibody screening policies and on kidney allocation in
our transplant setting (12). The objective was to iden-
tify an optimal antibody detection regimen which is




We analyzed a total of 1,421 sera from 1,395 patients
belonging to two groups.
The ﬁrst group consisted of 815 sera from 789
patients on the waiting list for a cadaveric kidney trans-
plant. Of these 723 had never been transplanted and
66 had returned to the waiting list following graft
failure.
The second group consisted of 606 patients who
underwent kidney transplantation at least six months
before the analysis (median 7 years; range 6 months–
29 years). The majority of these were primary trans-
plants using kidneys from a cadaver donor; however 46
individuals had received a second, ﬁve individuals a third
cadaver kidney transplant and 90 of the 606 transplants
were performed using living donors.
Sera were collected from both groups primarily to ena-
ble a large number of sera to be analyzed. The analysis
of the two groups was performed separately to maintain
homogeneity of each group and in addition also permit-
ted a comparison of the antibody proﬁles for each
situation.
Sera were collected from July to December 2004 and
all patients involved gave informed consent. Ethical ap-
proval for the study was granted on the condition that
the sera collected were screened for the purpose of
assessing patients for transplantation.
All kidney transplant recipients had a functioning graft
at the time of the study and were under immunosup-
pressive therapy.
CDC Methodology
A total of 1,421 sera were screened by CDC using a
whole lymphocyte population consisting of a panel of
52 cells from Caucasian blood donors incorporating the
HLA-A,-B, and -DR antigens normally detected in our
population. The CDC protocol used was the standard
method as previously published (13). In essence recipi-
ents’ sera (1 ll) were dispensed onto Terasaki trays (One
Lambda, CA, U.S.A.) and positive and negative controls
included for the purpose of quality control. The negative
control comprised sera from male untransfused, group
AB blood donors. The positive control was pooled sera
obtained from patients with a PRA greater than 80%.
The trays were either used immediately or stored at
408C. Fresh donor cells [1 ll of a 2 3 106/ml suspen-
sion in Hanks solution (Euroclone, Italy)] were added to
the recipient’ sera and the trays incubated at 228C for 60
min. Rabbit complement (5 ll) was added to each well
and the trays incubated for a further 60 min at 228C.
Finally a cell staining solution composed of acridine or-
ange, ethidium bromide, and quenching ink (Fluoro-
quench, OneLambda, U.S.A.) was added to each well of
the tray. The trays were read using a dual-phase ﬂuores-
cent microscope (Leitz, Germany). Positive reactions
were scored when the number of lysed cells in each
well was 20% or more, negative reactions were scored
for wells with 0–20% cell death. The number of lysed
cells in the negative and positive control wells was
monitored for each tray. The percentage of panel reac-
tive antibodies (PRA) was calculated and the speciﬁcity
evaluated with the support of LAMBDA SCAN ANALYSIS
software.
Testing for the Presence of IgM Isotype Antibodies
Sera that gave a positive result with CDC but a nega-
tive result with the Luminex method were retested with
and without dithiotritol (DTT) present to differentiate
between IgM and IgG antibodies.
Luminex Methodology
Antibody screening and identiﬁcation of antibody speci-
ﬁcity were carried out using a LABScan 100 Flow analyser
(Luminex Corporation, Texas, USA). The products utilized
were LABScreen Mixed kit (One Lambda, CA, USA) and
LABScreen PRA. The former method simultaneously
detects Class I and Class II antibodies using micro beads
coated with puriﬁed Class I and Class II HLA antigens and
the latter establishes the percentage PRA and speciﬁcity
for Class I and II. The tests were carried out according to
the manufacturer’s instructions and the analysis was per-
formed with One Lambda software (HLA visual 1.1). The
same lot number for the Luminex products was used for
all sera to avoid any lot to lot variability.
The cut-off value was calculated using negative sera
(Blood group AB sera from 27 un-transfused healthy
males). A mean value and three standard deviations were
calculated obtaining a cut-off value of 3.0 with an ambig-
466 COLOMBO ET AL.
Cytometry Part B: Clinical Cytometry DOI 10.1002/cyto.b
uous area from 2.5 to 3.0. The cut-off value was dis-
cussed with the manufacturers who advised that the cut-
off value of 3.0 was appropriate. Sera with equivocal
results (a value between 2.5 and 3.0) were considered
borderline positive and therefore retested to elucidate
any ambiguity.
A Qualitative Comparison of the Sera Positive by the
Luminex and CDC Methods
The results for all sera that were positive for anti-HLA-
Class I antibody speciﬁcities by the Luminex method
were compared to the results for the same sera tested
by the CDC method to determine if any HLA Class I anti-
body speciﬁcities were consistently missed by the CDC
method. Any speciﬁcities that were detected by the
Luminex system but undetected in the same serum by
the CDC method were recorded. The number of sera
(i.e. incidences) where each particular speciﬁcity was
detected by the Luminex and the CDC method was also
noted in order to determine the frequency of detection
of each antibody speciﬁcity for each method.
A Comparison of Antigen Representation for Both the CDC
and Luminex Methods
To contrast antigen frequencies of the CDC panel (52
cells) to that of the Luminex LABScreen PRA system (55
microspheres) the representation of antigens most fre-
quently observed in the Italian Caucasoid population
was determined by expressing the number of cells/
microspheres expressing a particular antigen as a per-
centage of the total number of cells/microspheres used.
Statistical Analysis
To determine any statistically signiﬁcant differences in
the detection of HLA antibody speciﬁcities between the
two methods the percentage of positive samples were
compared using 2 3 2 contingency tables using v2 and
Fisher exact analysis with the level of signiﬁcance set at
P < 0.05 and 95% conﬁdence intervals (95% CI). All
analyses were performed using The SAS version 9.1
(Cary, NC, USA).
The study was performed in 4 steps:
1. All sera were tested for the presence of anti-HLA
antibodies with CDC and with the LABScreen Mixed kit
(One Lambda, 21001 Kittridge Street, Canoga Park, CA,
USA) with the aim of comparing the results from the
two screening methods.
2. All sera positive or borderline positive with LAB-
Screen Mixed kit were re-tested with the LABScreen PRA
to identify the antibody speciﬁcity and conﬁrm the
screening results.
3. The sera positive only with CDC were tested with
and without DTT in order to exclude the presence of
IgM isotype antibodies.
4. All samples with discrepant results for CDC test
versus Luminex LABScreen PRA test were re-tested in
order to eliminate any technical error.
RESULTS
In the waiting list patient group the total number of
sera testing positive for the presence of anti-HLA anti-
bodies with the Luminex protocol was 149/815 (18%)
versus 63/815 (8%) (P < 0.0001) with CDC and similar
percentages were found in the 606 transplanted patients
(19% vs. 8%) (P < 0.0001). The CDC whole lymphocyte
method did not identify any anti-HLA Class II antibodies
speciﬁcities in any of the sera tested for both groups of
patients whereas 191/1421 sera tested positive for anti-
HLA Class II antibodies with the Luminex method. Anti
HLA Class I antibodies recognise HLA Class I antigens
present on T lymphocytes and Anti HLA Class II antibod-
ies recognise HLA Class II antigens present on B lympho-
cytes. The low numbers of B lymphocytes present in the
whole lymphocyte population used in the CDC test are
the likely explanation why anti-Class II HLA antibodies
were not detected by this method.
All samples that tested positive with the CDC method
but were negative with the Luminex LabScreen Mixed
test were retested by the CDC method with and without
DTT. In all cases (n ¼ 32) the sera were negative follow-
ing the DTT test. Because of the above observations
only sera that tested positive for Class I by the Luminex
method (antibodies of the IgG isotype only) were com-
pared to sera that tested positive and were DTT resistant
with the CDC method (likely to be IgG isotype only) in
order to ensure a valid direct comparison. The analyses
of the sera positive for Class I IgG anti-HLA antibodies
from the group of patients on the waiting list and from
the transplanted patients are shown in Tables 1 and 2
respectively. The anti-HLA Class II antibody data for the
Luminex method and the results of the DTT testing for
the CDC method are described below.
Analysis of Sera Taken from Patients on the Waiting List
Concordance between the results for the Luminex
Screen and the CDC test was calculated as the number
of samples that gave the same result (either negative or
positive) by both methods expressed as a percentage of
the total number of sera tested. The analysis of sera posi-
tivity shown in Table 1 identiﬁed a concordance of 92%
between the Luminex and CDC methods for the identiﬁ-
cation of anti-HLA Class I IgG speciﬁc antibodies.
In terms of discordant results, 66 of the 788 sera
(8.5%) which tested positive by the Luminex screen test
were negative when tested using the CDC test (P <
0.0001). Conversely 7 (0.9%) of the sera which tested
positive by the CDC method were negative with the
Luminex screen; however all 7 of these sera were nega-
tive following DTT treatment and therefore were
reported in Table 1 as both CDC and Luminex negative
for IgG isotype anti-HLA Class I antibodies.
The Luminex method detected anti-HLA Class II anti-
bodies in 99 (12%) of the 815 sera tested in this group
of patients; 27/815 (3%) sera were positive for Class II
only and 72/815 (9%) for both Class I and II simultane-
ously. Of the 149 sera testing positive the distribution
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for Class I only, Class II only, and Class I and II antibod-
ies simultaneously was 34, 18, and 48% respectively.
Analysis of Sera Taken from the Transplanted Patients
The anti-HLA Class I antibody analysis demonstrated a
concordance of 91% between the CDC and Luminex
methods in the group of transplanted patients as shown
in Table 2. Of the sera tested, 49/560 (8.7%) were posi-
tive using the Luminex method but negative by the CDC
test (P < 0.0001).
Of the 606 sera, 92 (15%) tested positive for anti-HLA
Class II antibodies with the Luminex method, 46/606
(7.5%) for Class II only and 46/606 (7.5%) for both Class
I and II simultaneously. Of the total of 116 sera that
tested positive the distribution for Class I only, Class II
only and Class I and Class II antibodies simultaneously
was 20, 40, and 40% respectively.
The number of DTT sensitive sera (i.e. IgM isotype
antibodies were present) were higher in this group
when compared to the group of patients on the waiting
list; 25/606 (4%) (P < 0.0001) of sera tested positive
with the CDC test and negative with Luminex but were
negative with the CDC method following DTT treatment
(vs. 7/788 (0.9%) for the pretransplant group).
We also observed differences in antibody proﬁle
between the group of patients on the waiting list and
the group of patients that had been transplanted. The
two groups showed differences in the distribution of
anti-HLA Class I and anti-HLA Class II antibodies. In par-
ticular in the transplanted patient group the percentage
of sera positive for anti-HLA Class II antibodies only was
higher when compared to the waiting list group (40%
vs. 18%) (P < 0.0001).
Analysis of Cut-off Value for Luminex Screen Test
The total number of sera testing positive by the Lumi-
nex screen for all patients from both groups was 265, of
these, 11 sera (4%) were positive by the LABScreen
Mixed test (i.e. had a value greater than the cut-off value
of 3), but tested negative in a subsequent analysis with
LABScreen PRA, therefore no anti-HLA antibody speciﬁc-
ity was identiﬁed in these sera. Of the 68 sera that were
borderline positive (i.e. had a value between 2.4 and
2.99) with the LABScreen Mixed test, 44 (65%) were
conﬁrmed positive when tested with LABScreen PRA for
anti-HLA antibody speciﬁcity. All 44 sera had a previous
sensitization event (e.g., pregnancy, blood transfusion, or
organ transplantation). Of the sera that had a reading
above the cut-off value with the LABScreen Mixed Lumi-
nex technique 96% corresponded with the positive iden-
tiﬁcation of HLA speciﬁc antibodies when tested with
the Luminex LABScreen PRA.
Comparison of the Detection of Anti-HLA Class I IgG
Isotype Antibodies by CDC vs. Luminex Methodologies
Although there is a high concordance rate for the
detection of HLA Class I IgG isotype antibodies between
the two techniques (92% and 91% for the waiting list
and transplanted patient groups respectively), the
Luminex method detected anti-HLA Class I antibodies in
an additional 115 sera which tested negative for anti-
HLA-Class I antibodies with the CDC technique. The dif-
ferences in antibody detection between the CDC and
Luminex method were statistically signiﬁcant for both
the waiting list and post-transplant patient groups (P <
0.0001 Fishers exact test).
A Qualitative Comparison of the Sera Positive by the
Luminex and CDC Methods
This analysis was performed for the transplanted
group of patients as post-transplant follow-up data would
be available to assess the clinical impact of the antibod-
ies detected. A comparison of samples positive by both
Luminex LABScreen Mixed and LABScreen PRA i.e. an
antibody speciﬁcity was identiﬁed (n ¼ 65) and where
speciﬁcities were determined by the CDC panel (n ¼
21) was carried out and the data are shown in Table 3.
Table 2
Comparison Between CDC and LABScreen Mixed Results for anti-HLA Class I IgG Antibodies Detected in Sera from
Transplanted Patientsa
Class I IgG only CDC positive N. (%) CDC negative N. (%) Total N. (%)
Luminex positive 21 (3.8) 49 (8.7) 70 (12.5)
Luminex negative 0 (0) 490 (87.5) 490 (87.5)
Total 21 (3.8) 539 (96.2) 560b
aP < 0.0001.
b46/606 sera (7.5%) were positive for HLA Class II antibodies and 46/606 (7.5%) for Class I and II simultaneously according to
the Luminex methodology. The percentage values shown in Table 1 are expressed in relation to the total number of sera tested that
were not Class II positive only i.e. 560.
Table 1
Comparison Between CDC and LABScreen Mixed Results for
Anti-HLA Class I IgG Antibodies Detected in Sera from
Patients on the Waiting List for a Kidney a
Class I IgG only
CDC positive CDC negative Total
N. (%) N. (%) N. (%)
Luminex positive 56 (7.1) 66 (8.5) 122 (15.5)
Luminex negative 0 (0) 666 (84.5) 666 (84.5)
Total 56 (7.1) 759 (92.9) 788b
aP < 0.0001.
b27/815 sera (3%) were positive for HLA Class II antibodies
only and 72/815 (9%) for both Class I and Class II according
to the Luminex methodology. The percentage values shown in
Table 1 are expressed in relation to the total number of sera
tested that were not Class II positive only i.e. 788.
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For simplicity the comparison was limited to the anti-
HLA-A and anti-HLA-B antibodies detected and did not
include anti-HLA-C antibodies as the consensus is that
these antibodies are less clinically relevant. The data as
recorded in Table 3 showed that some of the Class I anti-
body speciﬁcities were detected more frequently by the
Luminex than the CDC method. In particular these were
HLA-A2, -A9, -A28, -A32, HLA-B44, -B49, and -B27. When
the detection rate for these speciﬁcities was compared
for the two methods (the number of times the speciﬁcity
was detected in the total number of sera tested, n ¼
606), the Luminex method appeared to be statistically
signiﬁcantly more sensitive for the speciﬁcities HLA-A9
(P ¼ 0.009), -A32 (P ¼ 0.03), and HLA-B27 (P ¼ 0.007).
The frequencies of these antigens in the Italian Cauca-
soid population are 28, 10, and 4% respectively (www.
allelefrequencies.net).
To address the question of whether these speciﬁcities
were under-represented on the CDC cell panel Table 4
was consulted and the representation on the test panels
(number of cells vs. number of beads was comparable
for both methods).
A Comparison of Antigen Representation for Both the CDC
and Luminex Methods
Table 4 showed that the representation of the antigens
HLA-A9 (24% vs. 21%), and HLA-A32 (11% vs. 13%) and
the HLA-B27 (5% vs. 2%) panel antigen was comparable
for both the Luminex and CDC techniques and not statis-
tically signiﬁcantly different. A number of antibody spe-
ciﬁcities were not detected in any sera by the CDC
method despite the fact that the antigens were present
on the test panel. Only three antibody speciﬁcities (HLA-
B53, -B67, and -B81) were identiﬁed by Luminex yet
missed by CDC where the antigen was absent from the
CDC panel and this occurred in two sera for each of
these speciﬁcities.
Analysis of Clinical Relevance of Antibodies Detected by
the Luminex and CDC Methods
In the series of transplanted patients, we found that
50% of subjects with positive sera had anti-HLA antibod-
ies that were donor-speciﬁc. This value is comparable to
the ﬁndings from a previous study (14). All subjects posi-
tive with Luminex technique alone (n ¼ 188) had an an-
amnesis positive for immunological stimuli such as trans-
Table 4
The Percentage Representation of the Most Frequent Antigens
Present in the Italian Population for Both the CDC Cell Panel
and the Luminex Beadsa
Method used



























aThe CDC panel consisted of 52 fresh cells and the Luminex
system used 55 microspheres.
bAll 8 cells represented the A68 split of A28, A69 was not
represented.
cBoth A68 and A69 splits of A28 were represented (An
anti-A69 antibody was detected in only one serum by Lumi-
nex).
dThe CDC panel had only the A25 and A26 splits present
wheras the Luminex panel had all A10 splits represented.
eAll A19 splits were represented by both the CDC and Lumi-
nex panels.
Table 3




Number of sera HLA-B
antibodies
Number of sera
Luminex CDC Luminex CDC
A1 3 1 B7 2 0
A2 14 8 B8 1 0
A3 4 1 B12 6 2
A9 13 2 B13 3 1
A10 (25) 6 2 B14 1 0
A11 8 2 B21 (49) 4 0
A28 10 3 B22 2 0
A29 1 0 B27 8 0
A30 1 0 B35 1 0
A31 1 0 B40 3 0
A32 6 0 B41 2 0





The above table compares the number of sera i.e. inciden-
ces when the Luminex system was able to detect a speciﬁcity
to the CDC method.
aThese speciﬁcities were not represented on the CDC panel-
see Table 4. The antibody speciﬁcities highlighted in bold were
detected statistically signiﬁcantly more frequently with the
Luminex method when compared to the CDC method. A number
of antibody speciﬁcities were detected by Luminex but unde-
tected by CDC despite the antigens being represented on the
CDC panel.
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fusions, failed transplants or pregnancies with the excep-
tion of ﬁve females and three males. Two patients who
tested negative with the CDC test pre-operatively
experienced acute rejection of their transplanted kidney.
Retrospective analysis of the same sera using the Lumi-
nex system detected the presence of donor speciﬁc anti-
HLA Class I antibodies.
DISCUSSION
Individuals become sensitized following immunologi-
cal stimuli such as previous blood transfusions, pregnan-
cies, and failed transplants. Sensitization against HLA
antigens becomes a concern when, because of end-stage
organ failure, these individuals enter the waiting list for
an organ transplantation. Sensitization against HLA anti-
gens because of the presence of allo IgG antibodies not
only prolongs waiting times but it has also been corre-
lated with an increased risk of graft failure (2,3).
Patient sensitization has traditionally been deﬁned on
the basis of PRA screening results generated from com-
plement-dependent cytotoxicity assays and the level of
sensitization is expressed by %PRA. This method of deﬁ-
nition has some limitations because it is dependent on
panel composition and therefore several alternative or
supplementary tests have been developed in the last
decade. These new methodologies such as Flow Cytome-
try are based on solid-phase assays, and have demon-
strated greater sensitivity and speciﬁcity with respect to
CDC (5,6,15). In our laboratory, clinical relevance, cost
implications and staff resources have limited the use of
Flow Cytometry to selected cases, namely pediatric sub-
jects and living related transplants. Such limitations
prompted us to assess an alternative technique hence
our evaluation of the recently developed Histocompati-
bility and Immunogenetics application of Luminex tech-
nology. In terms of consumables, manpower and capital
equipment we found Luminex technology less expensive
and more user friendly than Flow Cytometry. In addition
no particular expertise is needed for the data acquisition
phase of the Luminex techniques and the discrimination
between positive and negative reactions is simple and
clear relative to the alternative screening methods cur-
rently available. Collection of results using both the
Luminex and CDC methodologies for a large number of
samples collected from patients on the waiting list and
from patients who had received a kidney transplant pro-
vided considerable data for our retrospective study and
allowed us to compare the two techniques to ascertain
the optimum screening strategy.
The overall concordance between the two methods
was 85% however this comparison was not appropriate
as the two methods detect nonoverlapping antibody
population i.e., our whole lymphocyte population CDC
method detected IgM antibodies but did not identify anti
HLA-Class II antibody speciﬁcity and the Luminex
method detected both anti-HLA Class I and anti-HLA
Class II antibody speciﬁcities but only of the IgG isotype.
A direct comparison of the two methods for the detec-
tion of anti HLA Class I IgG antibodies alone revealed
that the Luminex method identiﬁed HLA speciﬁcities in
an additional 60% of the total number of sera which
screened positive for anti-HLA Class I antibodies using
the CDC method. According to the manufacturers, the
Luminex LAbScreen Mixed test is more sensitive but less
speciﬁc than the LABScreen PRA test, which resulted in
11 samples positive (cut-off above 3) by the screening
test but negative for HLA-speciﬁcities i.e. false positives
in our study. Similar 24/66 of the samples that screened
borderline positive (cutoff-2.4–2.99) were negative by
the LABScreen PRA test. This system prevents true posi-
tives being undetected and only resulted in a small per-
centage (4%) of false positives. The analysis of the sam-
ples that had a borderline cut-off for the Luminex
method, indicated that all samples with a borderline
result plus a sensitization history can be routinely
selected for further analysis with the LABScreen PRA
test.
Qualitative analysis of the performance of the two
methods demonstrated that the Luminex system was
able to detect a number of antibody speciﬁcities signiﬁ-
cantly more frequently than the CDC technique although
the representation of these antigens was comparable for
the test panels of both methods. The three antibody spe-
ciﬁcities identiﬁed by the Luminex method but unde-
tected by the CDC test where the antigens were absent
from the CDC panel were all of rare frequency so
unlikely to be included on a randomly selected CDC
panel such as for this study but may be of clinical rele-
vance. Therefore the Luminex panel not only allows bet-
ter detection of antigens that are commonly represented
in our patient population but prevents rare antibody spe-
ciﬁcities being missed.
These ﬁndings indicated that the screening and speci-
ﬁcity detection approach of the Luminex system using
the cut-off value as per this study is an accurate and sen-
sitive method for the identiﬁcation and determination of
the nature of a positive reaction.
The higher percentage of sera positive for anti-HLA
Class II antibodies proﬁle observed in the transplanted
patient group when compared to the group of patients
on the waiting list (40% vs. 18%) as detected by the
Luminex method may be a result of interaction between
donor antigen presenting cells/Class II HLA molecules
and recipient T cells via the direct recognition pathway,
typical of the early post-transplant phase. Monitoring of
these patients post transplant requires an appropriately
sensitive antibody protocol but in addition the clinical
relevance of the antibodies needs to be clearly estab-
lished. The analysis of the data of clinical relevance of
the antibodies detected by the Luminex and CDC
method indicated that the antibodies detected by Lumi-
nex alone were of clinical importance and corresponded
with a sensitization event; however the CDC failed in
two cases to detect antibodies crucial to transplant out-
come. We are currently collecting data relating to graft
outcome on all patients to determine whether the appa-
rently increased sensitivity of the Luminex method
observed in both groups of patients in this study impacts
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on graft and patient survival. Previous studies on this
subject give conﬂicting results (14,16).
The percentage of sera with IgM isotype antibodies
present was also higher in the transplanted group when
compared to the patients on the waiting list (4% vs.
0.9%). This may be explained by the fact that the trans-
planted group of patients are immunosuppressed and as
a result have more infections and in addition may have
an increase in systemic inﬂammation following transplan-
tation. Both of these factors may contribute to increased
levels of IgM production, however the clinical relevance
of the presence of IgM antibodies remains controversial
(5,17,18). Nonetheless the DTT integrated CDC method
readily facilitates the detection of both the IgG and the
IgM isotype antibodies within the same test.
This study provided not only quantitative but also
qualitative analysis of the performance of our CDC
method relative to the Luminex screening technique.
Based on this comparison we have developed the follow-
ing antibody screening strategy: all new patients entering
the waiting list are tested with both CDC and Luminex
LABScreen Mixed tests, and speciﬁcity deﬁnition analyzed
as appropriate using Luminex LABScreen PRA. An auto-
cross match and treatment of sera with DTT are also car-
ried out on samples positive only with the CDC method.
The CDC method is labor intensive and procurement of
appropriate cells sometimes difﬁcult however, we believe
that the maintenance of CDC in addition to Luminex,
allows greater conﬁdence in cross-match results (as CDC
is our method of choice for crossmatching prior to trans-
plantation) and the ability to detect IgM in addition to
IgG anti-HLA speciﬁc antibodies.
The advantages of the integrated use of Luminex and
CDC are as follows:
1. Easy discrimination between antibodies speciﬁc for
HLA Class I and Class II antigens.
2. Provision of information on acceptable mismatches
in the cases of highly sensitized patients.
3. Increased rate of antibody detection when com-
pared with CDC alone.
4. Avoids the need for B cell separation for CDC testing
yet facilitates through detection of Class II speciﬁcities.
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